FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2919185512> ?p ?o ?g. }

• W2919185512 endingPage "2355" @default.
• W2919185512 startingPage "2355" @default.
• W2919185512 abstract "Abstract Background and Objectives: Genetic therapy relieves transfusion-dependence in patients 12 years and older with ß-Thalassemia (1) There is an urgent need to develop a complementary approach to genetic therapy for children younger than 12 years of age. The objective of this report is to describe the potential development of an extracellular superoxide dismutase-mimetic (SOD3-mimetic) to relieve sickle cell disease (SCD) children susceptible to stroke from being transfusion-dependent in order to avoid stroke. SanFlow [aka polynitroxylated pegylated hemoglobin (PNPH)], a SOD3-mimetic has been evaluated and approved by the FDA for further development as drug for the treatment of traumatic brain injury (TBI) complicated by hemorrhagic shock (HS), stroke, and SCD. PK&PD studies demonstrated that SanFlow works as a macromolecular SOD3-mimetic by protecting the endogenous vascular nitric oxide (NO) leading to enhanced blood flow. SanFlow has been shown to protect against superoxide induced hypoxia and inflammation in transgenic SCD and rat model of ischemic stroke as well as a mouse model of TBI+HS. In a rat middle cerebral artery occlusion (MCAO) model of stroke the spreading of the hypoxic core of the ischemic brain as measured by Pial arterial diameter is maintained over 2 hours post onset of stroke with associated reduction in inflammatory markers and brain infraction (3). In a mouse TBI+SH model, SanFlow was shown to be superior to fresh shed whole blood. The safety and efficacy of SanFlow was tested over a 50 fold dose range (i.e. from 0.1 to 5 times the shed blood volume). SanFlow was shown to work at extremely low volume in conjunction with volume replacement crystalloid to substitute whole blood resuscitation (3). Experimental Results: Using Berkeley model of sickle mice (Hba0/0 Hbb0/0Tg (HuminiLCRα1GγAγδβS) we have measures the PK&PD of SanFlow as a complementary or a substitute for genetic therapy. We have non-invasively measured the blood flow and vasoconstriction using transgenic SS mice (N=7) against WT littermates (N=4) as control. A single bolus dose of SanFlow (20ml/kg at hemoglobin of 4g/dl) significantly corrected the aortic stiffness and pulmonary flow of the SS mice to that of WT littermates (P<0.05). This is also correlated with the decrease of superoxide level in the lung as measure by Luminol activity assays (which fluoresces in the presence of superoxide) (P<0.05). Plasma cGMP (downstream effector of NO and natriuretic peptide activity) and NOx (breakdown product of NO and a measure of NOS activity) concentrations were measured in plasma of mice after infusion of SanFlow. SanFlow infusion was shown to significantly increased plasma cGMP concentrations in plasma. SanFlow infusion also resulted in a significant increase in NOx in plasma after infusion (P<0.05). SanFlow resulted in an increase in plasma cGMP and NOx in SS mice. Thus, the pathophysiological defects or difference of SS mice and WT littermates are corrected by SanFlow infusion. Conclusions:The present results support development of SanFlow, delivered through continuous infusion, for anemic SCD children to prevent the development of blood transfusion dependency in order to avoid stroke and painful vaso-occlusive crisis (VOC). These results also demonstrated that SanFlow can be used safely and effectively in the elimination of serious painful vaso-occlusive crisis and protect silent and major strokes. Clinical trials of SanFlow in SCD children, prior to their transfusion dependence, as well as in transfusion-dependent teenagers and adults with SCD patients are warranted. By extension, ß-Thalassemia patients can also be treated like SCD patients using SanFlow to relieve them from dependence on life-long blood exchange transfusion. However, these patients would be treated with SOD3-mimetic while waiting for genetic therapy. References: Thompson AA., et.al. Eng. J. Med 2018; 398: 1479-1493 Brockman EC., et. al. 2017 Neurotrauma, 34(7):1337-50 Cao S., et. al. 2017 J. Am Heart Assoc., 6(9):e006505. Disclosures Hsia: AntiRadical Therapeutics LLC: Employment." @default.
• W2919185512 created "2019-03-11" @default.
• W2919185512 creator A5017436949 @default.
• W2919185512 creator A5053031082 @default.
• W2919185512 date "2018-11-29" @default.
• W2919185512 modified "2023-09-30" @default.
• W2919185512 title "SOD3-Mimetic As a Complement for Genetic Therapy in Sickle Cell Disease" @default.
• W2919185512 doi "https://doi.org/10.1182/blood-2018-99-120287" @default.
• W2919185512 hasPublicationYear "2018" @default.
• W2919185512 type Work @default.
• W2919185512 sameAs 2919185512 @default.
• W2919185512 citedByCount "1" @default.
• W2919185512 countsByYear W29191855122023 @default.
• W2919185512 crossrefType "journal-article" @default.
• W2919185512 hasAuthorship W2919185512A5017436949 @default.
• W2919185512 hasAuthorship W2919185512A5053031082 @default.
• W2919185512 hasConcept C126322002 @default.
• W2919185512 hasConcept C127413603 @default.
• W2919185512 hasConcept C157767197 @default.
• W2919185512 hasConcept C178790620 @default.
• W2919185512 hasConcept C185592680 @default.
• W2919185512 hasConcept C2779817106 @default.
• W2919185512 hasConcept C2780014101 @default.
• W2919185512 hasConcept C2780645631 @default.
• W2919185512 hasConcept C2781458332 @default.
• W2919185512 hasConcept C540031477 @default.
• W2919185512 hasConcept C71924100 @default.
• W2919185512 hasConcept C7836513 @default.
• W2919185512 hasConcept C78519656 @default.
• W2919185512 hasConceptScore W2919185512C126322002 @default.
• W2919185512 hasConceptScore W2919185512C127413603 @default.
• W2919185512 hasConceptScore W2919185512C157767197 @default.
• W2919185512 hasConceptScore W2919185512C178790620 @default.
• W2919185512 hasConceptScore W2919185512C185592680 @default.
• W2919185512 hasConceptScore W2919185512C2779817106 @default.
• W2919185512 hasConceptScore W2919185512C2780014101 @default.
• W2919185512 hasConceptScore W2919185512C2780645631 @default.
• W2919185512 hasConceptScore W2919185512C2781458332 @default.
• W2919185512 hasConceptScore W2919185512C540031477 @default.
• W2919185512 hasConceptScore W2919185512C71924100 @default.
• W2919185512 hasConceptScore W2919185512C7836513 @default.
• W2919185512 hasConceptScore W2919185512C78519656 @default.
• W2919185512 hasIssue "Supplement 1" @default.
• W2919185512 hasLocation W29191855121 @default.
• W2919185512 hasOpenAccess W2919185512 @default.
• W2919185512 hasPrimaryLocation W29191855121 @default.
• W2919185512 hasRelatedWork W1968110890 @default.
• W2919185512 hasRelatedWork W1981777914 @default.
• W2919185512 hasRelatedWork W1986094463 @default.
• W2919185512 hasRelatedWork W2007850013 @default.
• W2919185512 hasRelatedWork W2047398389 @default.
• W2919185512 hasRelatedWork W2080002007 @default.
• W2919185512 hasRelatedWork W2386075408 @default.
• W2919185512 hasRelatedWork W320380693 @default.
• W2919185512 hasRelatedWork W4382918250 @default.
• W2919185512 hasRelatedWork W2591875845 @default.
• W2919185512 hasVolume "132" @default.
• W2919185512 isParatext "false" @default.
• W2919185512 isRetracted "false" @default.
• W2919185512 magId "2919185512" @default.
• W2919185512 workType "article" @default.